Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
icosapent ethyl + rosuvastatin + ezetimibe
- Development stage
- Preclinical
- Lead developer
- Althera Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Icosapent ethyl + rosuvastatin + ezetimibe is an oral fixed-dose combination therapy developed by Althera for the management of dyslipidemia and cardiovascular risk. This triple-combination product utilizes a multi-pathway approach to lipid management: icosapent ethyl (a purified eicosapentaenoic acid ethyl ester) reduces triglyceride levels and exerts anti-inflammatory effects; rosuvastatin inhibits HMG-CoA reductase (HMGCR) to decrease endogenous cholesterol synthesis; and ezetimibe inhibits the NPC1L1 transporter to reduce intestinal cholesterol absorption. By combining these three agents, the therapy aims to achieve significant reductions in LDL-cholesterol and triglycerides while addressing residual inflammatory risk in patients with high cardiovascular risk.
- Other names
- Icosapent Ethyl/Rosuvastatin/Ezetimibe 4/40/10Icosapent Ethyl/Rosuvastatin/Ezetimibe 4/20/10Icosapent Ethyl/Rosuvastatin/Ezetimibe 4g/10/10mg
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on icosapent ethyl + rosuvastatin + ezetimibe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on icosapent ethyl + rosuvastatin + ezetimibe.